Corticosteroids lower mortality in hospitalized patients with COVID-19 pneumonia requiring oxygen support. In this observational retrospective study (September 2020-June 2021), we explored the association between receiving home corticosteroids without oxygen supply and 30-day mortality in hospitalized patients with COVID-19 pneumonia. Among a total of 794 COVID-19 pneumonia patients, 763 were included into the study (males 68%; mean age 65 +/- 12 years), of whom 197 (26%) received home corticosteroids (mean daily prednisone equivalent-dose 40 mg +/- 12 mg; range 10-50 mg; median 50 mg; IQR 25-50 mg; for 4 days). The overall 30-day mortality of the study population was 12%. The risk of death-adjusted for age, comorbidities, administration of remdesivir and respiratory failure severity-was lower (HR 0.405; p = 0.024) in patients receiving home corticosteroids. After stratifying the study population by age categories, home corticosteroids were associated with an adjusted decrease in mortality risk in patients > 77 years (HR 0.346; p = 0.040). Home corticosteroids may lower the 30-day mortality in elderly COVID-19 patients.

Potential of outpatient steroid therapy in elderly patients with early COVID-19

Luzzati, Roberto
;
De Luca, Marina;Sanson, Gianfranco;Borelli, Massimo;Biolo, Gianni;Giacomazzi, Donatella;Di Bella, Stefano
2022

Abstract

Corticosteroids lower mortality in hospitalized patients with COVID-19 pneumonia requiring oxygen support. In this observational retrospective study (September 2020-June 2021), we explored the association between receiving home corticosteroids without oxygen supply and 30-day mortality in hospitalized patients with COVID-19 pneumonia. Among a total of 794 COVID-19 pneumonia patients, 763 were included into the study (males 68%; mean age 65 +/- 12 years), of whom 197 (26%) received home corticosteroids (mean daily prednisone equivalent-dose 40 mg +/- 12 mg; range 10-50 mg; median 50 mg; IQR 25-50 mg; for 4 days). The overall 30-day mortality of the study population was 12%. The risk of death-adjusted for age, comorbidities, administration of remdesivir and respiratory failure severity-was lower (HR 0.405; p = 0.024) in patients receiving home corticosteroids. After stratifying the study population by age categories, home corticosteroids were associated with an adjusted decrease in mortality risk in patients > 77 years (HR 0.346; p = 0.040). Home corticosteroids may lower the 30-day mortality in elderly COVID-19 patients.
Pubblicato
https://link.springer.com/article/10.1007/s40520-022-02181-1
File in questo prodotto:
File Dimensione Formato  
s40520-022-02181-1.pdf

non disponibili

Descrizione: Per tutta la durata dell'emergenza COVID-19 l'articolo è liberamente accessibile dal sito dell'editore
Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 945.12 kB
Formato Adobe PDF
945.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/3025806
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact